Interestingly, patients harboring at least 1 mutation targeting one of the four genes of the NF-κB pathway “mutated” as compared to patients in the ABC-DLBCL group without mutations “unmutated” had a 3-year overall survival (OS) of 66.7% versus 26.1%, respectively (P = 0.0337) [20]. Here, NFKB1 is linked to diffuse large B-cell lymphoma.